August 2017 VOL 8, NO 8

JONS August 2017 Volume 8 Number 8

Letters from Lillie

Be “In the Know”—JONS Provides the Information Essential to Your Success as a Navigator

Lillie D. Shockney, RN, BS, MAS, ONN-CG 

Dear Navigators, Not only do navigators have an obligation to their patients, institutions, and themselves to understand and master core competencies of navigation, but they also need to remain up-to-date [ Read More ]

Original Research

The Relationships Between Psychosocial Factors and Group Cohesion in African American Women with Breast Cancer

Pearman D. Parker Hayne, MPH, RN, BSN1; Swann Arp Adams, PhD2; Sue P. Heiney, PhD, RN, FAAN1
1College of Nursing, University of South Carolina, Columbia, SC
2College of Nursing, Department of Epidemiology & Biostatistics, Arnold School of Public Health, University of South Carolina, Columbia, SC
 

Purpose: Nurse navigators and other nurses working with cancer survivors often lead patient and family support groups. An important component of a successful group is group climate, the relationships formed [ Read More ]

AONN+ West Coast Regional Meeting

Delving Deeper into the AONN+ Standardized Navigation Metrics

At the Academy of Oncology Nurse & Patient Navigators (AONN+) Annual Meeting in November 2016, the AONN+ Standardized Navigation Metrics Task Force unveiled the first standardized navigation metrics for measuring [ Read More ]

AONN+ West Coast Regional Meeting

The Art of Community-Based Patient Navigation

Community navigators assist patients and their families throughout the entire cancer care continuum, from screening and diagnosis through treatment and survivorship, all the way to palliative care and the end [ Read More ]

AONN+ West Coast Regional Meeting

Role Delineation in Oncology Navigation

Role delineation in oncology navigation can have a significant impact on patient outcomes and job satisfaction for navigators, according to Jennifer Bires, LICSW, Clinical Social Worker and Program Coordinator at [ Read More ]

AONN+ West Coast Regional Meeting

The Growing Burden of Financial Toxicity in Oncology

The burden of financial toxicity has become increasingly recognized in the US healthcare system over the past several years, according to Clara Lambert, BBA, Oncology Financial Navigator at Munson Medical [ Read More ]

AONN+ West Coast Regional Meeting

The Silo Mentality: Recognizing It and Avoiding It

Working with a silo mentality can be detrimental to the delivery of high-quality patient care. At the 2017 Academy of Oncology Nurse & Patient Navigators (AONN+) West Coast Regional Meeting, [ Read More ]

AONN+ West Coast Regional Meeting

There’s Power in Numbers: Establishing a Group Smoking Cessation Program

The Surgeon General’s warning against cigarette smoking was put on packs in 1965, and 50 years later, approximately 18% of Americans still smoke. Cigarettes cause almost all tobacco-related diseases and [ Read More ]

2017 American Oncology Society of Clinical Annual Meeting

Overcoming Barriers to Cost Transparency in Cancer Care

As the cost of cancer care continues to rise, it’s not just the patients’ finances that are affected. Recent research has linked high out-of-pocket costs to nonadherence and early discontinuation [ Read More ]

2017 American Society of Clinical Oncology Annual Meeting

Olaparib Is First PARP Inhibitor to Show Advantage in BRCA-Mutated Breast Cancer

The PARP inhibitor olaparib significantly improved progression-free survival (PFS) compared with standard chemotherapy in women with HER2-negative metastatic breast cancer with a germline BRCA mutation. Disease progression was delayed by [ Read More ]

2017 American Society of Clinical Oncology Annual Meeting

Alectinib a New Standard of Care for ALK-Positive NSCLC

Alectinib, a next-generation ALK inhibitor, was called a new standard of care for ALK-positive non–small cell lung cancer (NSCLC) based on results from the phase 3 ALEX clinical trial presented [ Read More ]

2017 American Society of Clinical Oncology Annual Meeting

Pembrolizumab Makes Inroads in Sarcoma Subtypes

The number of tumor types amenable to pembroliz­umab immunotherapy keeps expanding and now includes sarcoma, which has been difficult to treat. In the SARC028 phase 2 multicenter trial, reported at [ Read More ]

2017 American Society of Clinical Oncology Annual Meeting

Promising Survival Signal with Cediranib as Combination in Relapsed Ovarian Cancer

Oral cediranib, an investigational VEGF inhibitor, in combination with a PARP or chemotherapy inhibitor, appears to have a survival benefit in women with relapsed platinum-sensitive ovarian cancer, according to data [ Read More ]

Breast Cancer

Advancing High-Value Early-Stage Breast Cancer Care

Cancer costs are rising, but the implementation of evidence-based quality improvement strategies in early-stage breast cancer care can reduce costs and improve patient quality of life, according to Angie Meillier, [ Read More ]

2017 Annual Meeting of the American Association for Cancer Research

Excellent Responses to Atezolizumab in Small Subset of TNBC

Preliminary data show excellent and durable responses to atezolizumab in 10% of women with triple-negative breast cancer (TNBC), one of the most aggressive and difficult cancers to treat. One hundred [ Read More ]

2017 Annual Meeting of the American Association for Cancer Research

Novel Combo Boosts Immune Response in Melanoma

The novel combination of the investigational IDO pathway inhibitor indoximod plus pembrolizu­mab led to higher response rates in patients with advanced melanoma than what is seen with pembrolizumab alone, according [ Read More ]

2017 Annual Meeting of the American Association for Cancer Research

Transplant Questionable After CAR T-Cell Treatment in Relapsed B-ALL

CAR T-cell therapy achieved excellent responses in an updated report on a series of 50 patients with relapsed B-cell acute lymphoblastic leukemia (B-ALL) treated with CAR T-cells at Memorial Sloan [ Read More ]

Colorectal Cancer

New Approach to HER2-Positive Colorectal Cancer Promising

Using a “double whammy” of 2 HER2-directed therapies achieved a clinical benefit rate of 70% and an objective response rate (ORR) of 30% in patients with heavily pretreated, HER2-positive metastatic [ Read More ]

Lung Cancer

Longest Follow-Up in NSCLC Responders to Immunotherapy

In the longest follow-up on single-agent nivolumab to date, 5-year overall survival (OS) was 16% in patients with advanced non–small cell lung cancer (NSCLC) in updated results from a phase [ Read More ]